TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28364091
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (targeting systolic BP <140 mm Hg)
Study: 21480207
Drug: INCB018424 (JAK1
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB018424 (JAK1 and JAK2 inhibitor)
Study: 11734429
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 microg twice a day)
Study: 9413293
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg daily)
Study: 31147684
Drug: Volumetric modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric modulated arc therapy (VMAT) for GYN, rectal, H&N, and prostate cancer
Study: 31147684
Drug: Volumetric modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volumetric modulated arc therapy (VMAT) for prostate cancer
Study: 28814394
Drug: Mediterranean/low-carbohydrate (MED/LC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean/low-carbohydrate (MED/LC) diet plus 28 g walnuts/d
Study: 23395779
Drug: 250ml beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ml beetroot juice daily (active)
Study: 21214895
Drug: Tele‐health supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele‐health supported Community COPD Service (two home visits with a specialist COPD clinician and daily tele‐monitoring over eight weeks)
Study: 19172536
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of 17beta-estradiol (E(2) group)
Study: 17175485
Drug: Fetoscopic laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetoscopic laser therapy
Study: 10740633
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose CDDP plus 5-FU regimen
Study: 10740633
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy group (MMC and UFT)
Study: 6685628
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of [3H]‐dibromodulcitol (400 mg/m2)
Study: 6685628
Drug: Three smaller
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three smaller daily oral doses of [3H]‐dibromodulcitol (150‐180 mg/m2)
Study: 29894926
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline irrigation
Study: 19786378
Drug: Nattokinase combined
Normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase combined with red yeast rice (RYR) extract (300 mg of extract/capsule)
Study: 19786378
Drug: Nattokinase mono
Normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase mono formula (50 mg/capsule)
Study: 11375838
Drug: Patient-controlled IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled IV meperidine (50 mg/h or more)
Study: 11375838
Drug: Patient-controlled IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled IV meperidine (<50 mg/h)
Study: 8215265
Drug: Ceftriaxone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (75 mg/kg for children, 4 g for adults) for 5 days
Study: 8215265
Drug: Chloramphenicol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (60 mg/kg/day until defervescence, then 40 mg/kg/day) for 14 days
Study: 3114803
Drug: Promethazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (12.5 mg, 25 mg)
Study: 3114803
Drug: Cinnarizine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (30 mg)
Study: 25624389
Drug: Clonidine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (5 μg/kg per day, divided into 8 doses, with possible dose escalation to maximum of 12 μg/kg per day)
Study: 25624389
Drug: Morphine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.4 mg/kg per day, with possible dose escalation to maximum of 1 mg/kg per day)
Study: 20873903
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help based on cognitive behavioral therapy (CBTgsh)
Study: 18258639
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (792 mg/d)
Study: 16377385
Drug: Allopurinol, 100
Normalized name: Allopurinol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol, 100 to 300 mg/d
Study: 9264767
Drug: Leuprorelin 11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 11.25 mg every three months
Study: 9264767
Drug: Leuprorelin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 3.75 mg monthly
Study: 7886558
Drug: SK therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK therapy
Study: 7886558
Drug: rt-PA therapy
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA therapy
Study: 2429076
Drug: tibalosine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibalosine 150 mg daily for 1 week
Study: 2429076
Drug: naloxone (opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (opioid receptor antagonist)
Study: 24418368
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU kg(‐1) twice‐weekly prophylaxis regimen
Study: 24418368
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU kg(‐1) once‐weekly prophylaxis regimen
Study: 20108160
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Magnesium (Ca/Mg)
Study: 12845235
Drug: PMX-F treatment
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMX-F treatment (group A, n = 10)
Study: 12845235
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group B, n = 10)
Study: 10827659
Drug: Topical regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regular insulin (Iletin‐II) applied four times a day until healed
Study: 10827659
Drug: Solution containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution containing the same amount of zinc
Study: 8690827
Drug: Clomipramine (100‐250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (100‐250 mg/day)
Study: 3908497
Drug: 0.03% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% aqueous solution of Sanguinaria extract (active mouthrinse)
Study: 3908497
Drug: Placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation (aqueous solution with similar color and taste)
Study: 10624908
Drug: Acetaminophen 750
Normalized name: acetaminophen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 750 mg
Study: 8540713
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (dose levels ranging from 0.5 to 8.0 mg/kg of body weight)
Study: 1950383
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 to 200 mg per day)
Study: 7045606
Drug: cinoxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinoxacin (500 mg every 12 hours)
Study: 7045606
Drug: co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole every 12 hours)
Study: 31623250
Drug: 0.25 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 g/kg bodyweight DSP
Study: 31623250
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg bodyweight DSP
Study: 31623250
Drug: 360 g
Normalized name: OATMEAL 0.025 g in 360 g TOPICAL SHAMPOO [DHT X]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 g of 10% DSB
Study: 31623250
Drug: 360 g
Normalized name: OATMEAL 0.025 g in 360 g TOPICAL SHAMPOO [DHT X]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 g of 15% DSB
Study: 31623250
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg bodyweight DSE
Study: 31623250
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg bodyweight DSE
Study: 27657985
Drug: Biosimilar recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilar recombinant human growth hormone (r-hGH; Somatotropin)
Study: 27657985
Drug: Reference recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference recombinant human growth hormone (Genotropin®)
Study: 23647408
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day) for 6 weeks
Study: 17277729
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (not specified treatment)
Study: 7794079
Drug: TRAM flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAM flap breast reconstruction with radiation treatment
Study: 7794079
Drug: TRAM flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAM flap breast reconstruction without radiation treatment
Study: 28860712
Drug: Prophylaxis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis of constipation (lactulose 10 mL twice daily)
Study: 22795617
Drug: Kirtan Kriya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kirtan Kriya Meditation (KKM) for 12 min daily for 8 weeks
Study: 22795617
Drug: Relaxing Music
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing Music (RM) listening for 12 min daily for 8 weeks
Study: 15192072
Drug: rLH 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH 75 IU daily from GnRH antagonist initiation to hCG injection
Study: 11682661
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ramipril and felodipine ER (R+F)
Study: 10771837
Drug: Hyperglycemia (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (glucose level > or = 150 mg/dl)
Study: 3277475
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B (0.2 to 2 mg/kg total dose) for 2 to 6 days
Study: 28807030
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Ascorbic Acid
Study: 28807030
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Acetylsalicylic Acid
Study: 28807030
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (Control)
Study: 23715360
Drug: Salbutamol +
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol + Ipratropium bromide (3 doses of 2.5mg Salbutamol and 500mcg Ipratropium bromide)
Study: 23715360
Drug: Salbutamol only
Normalized name: Salbutamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol only (3 doses of 2.5mg)
Study: 22019576
Drug: Topiramate (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (4-week titration starting at 25 mg/day to a maximum of 100 mg/day followed by an 8-week maintenance)
Study: 17954698
Drug: Ceftobiprole 500
Normalized name: ceftobiprole medocaril sodium 667 MG (equivalent to ceftobiprole 500 MG) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftobiprole 500 mg every 12 h
Study: 17306393
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (RT) in addition to adjuvant systemic therapy
Study: 9164811
Drug: Standard intravenous-feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous-feeding solutions
Study: 9164811
Drug: Aluminum-depleted intravenous-feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-depleted intravenous-feeding solutions
Study: 9164811
Drug: Standard intravenous-feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous-feeding solutions (subgroup with no neuromotor impairment)
Study: 9164811
Drug: Aluminum-depleted intravenous-feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-depleted intravenous-feeding solutions (subgroup with no neuromotor impairment)
Study: 30882151
Drug: adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: adherence to medication
Study: 18515918
Drug: Fixed higher-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed higher-dose budesonide/formoterol (FHDBF)
Study: 18515918
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose fluticasone/salmeterol (FDFS)
Study: 16223399
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of magnesium sulphate 5% (1.0 ml)
Study: 16223399
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml of preservative‐free 0.9% sodium chloride
Study: 10208945
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of salbutamol by jet nebuliser
Study: 10208945
Drug: Up to
Normalized name: Nubasics Soup Tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 10 puffs of salbutamol 100 microg by metered dose inhaler and spacer
Study: 1693335
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral treatment
Study: 1693335
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral treatment
Study: 1693335
Drug: Subcutaneous hyposensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous hyposensitization regime
Study: 606781
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza A/New Jersey/X-53 subunit virus vaccine (100 or 200 CCA units for children ≤9 years; 200 or 400 CCA units for children >9 years), administered intramuscularly in two doses at intervals of four weeks.
Study: 26226884
Drug: Donepezil (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (3, 5, and 10 mg)
Study: 23536583
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering therapy (INT)
Study: 21959068
Drug: Valerian (255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian (255 mg, 3 times daily for 3 days)
Study: 18810398
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 500 mg orally
Study: 18810398
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 500 mg orally combined with chloroquine (CQ) 750 mg
Study: 18810398
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 50 mg intravenous (i.v.)
Study: 18810398
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 750 mg administered orally alone
Study: 17971947
Drug: ADV 10
Normalized name: ADV-TK
DrugBank: Aglatimagene besadenovec (DB15074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV 10 mg/d for 48 weeks
Study: 17971947
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 24 weeks followed by ADV 10 mg/d for 24 weeks
Study: 15512809
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg valacyclovir orally every 8 h
Study: 15512809
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg valacyclovir orally every 8 h
Study: 11368294
Drug: ZD1839 (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD1839 (100mg once daily for 3 days)
Study: 11368294
Drug: Single 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 50mg dose of ZD1839 with food
Study: 9487372
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose total-body irradiation (STBI) - 10 Gy to midplane, 8 Gy to lungs
Study: 9487372
Drug: LOW instantaneous
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW instantaneous dose rate group (< or = 0.048 Gy/min)
Study: 9487372
Drug: MEDIUM instantaneous
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDIUM instantaneous dose rate group (> 0.048 and < or = 0.09 Gy/min)
Study: 9487372
Drug: HIGH instantaneous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH instantaneous dose rate group (> 0.09 Gy/min)
Study: 9487372
Drug: Treatment after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after 1985
Study: 9487372
Drug: Cataract incidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataract incidence influenced by instantaneous dose rate
Study: 8306272
Drug: 131I-Mu-9 immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I-Mu-9 immunoglobulin G
Study: 8306272
Drug: Both 131I-Mu-9
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both 131I-Mu-9 immunoglobulin G and 131I-F(ab')2
Study: 3178928
Drug: Maxepa (3.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxepa (3.24 g eicosapentaenoic acid and 2.16 g docosahexaenoic acid per day)
Study: 824725
Drug: Diftalone 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diftalone 500 mg/day
Study: 824725
Drug: Indomethacin 50-75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50-75 mg/day initially and 100 mg/day subsequently
Study: 31118245
Drug: Efgartigimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efgartigimod (10 mg/kg IV)
Study: 28378467
Drug: Ephedrine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (6 mg boluses)
Study: 28378467
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 μg boluses)
Study: 24382638
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) 750 mg q8h plus peginterferon (180 μg/week) and ribavirin (1,000-1,200 mg/day)
Study: 21500996
Drug: Estroprogestagen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estroprogestagen therapy (EP)
Study: 11734711
Drug: Serogroup B
Normalized name: Meningococcus serogroup B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (2 doses)
Study: 11734711
Drug: Serogroup B
Normalized name: Meningococcus serogroup B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC (3 doses)
Study: 11734711
Drug: Serogroup B
Normalized name: Meningococcus serogroup B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup B meningococcal vaccine VA‐MENGOC‐BC
Study: 9403267
Drug: Povidone-iodine (PVP-I)
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine (PVP-I) ethanol solution
Study: 29868911
Drug: High-nitrate (HN)
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-nitrate (HN) vegetables (∼200 g/d; ∼150 mg nitrate/d)
Study: 29868911
Drug: Low-nitrate (LN)
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-nitrate (LN) vegetables (∼200 g/d; ∼22 mg nitrate/d)
Study: 29868911
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no increase in vegetables; ∼6 mg nitrate/d)
Study: 23553866
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg fluoride
Study: 23553866
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fluoride
Study: 23553866
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluoride
Study: 19682880
Drug: Escin (60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin (60mg daily, 30mg every 12 hours for 2 months)
Study: 15826880
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (5 mg daily, n = 36)
Study: 12812355
Drug: Mefloquine-artesunate (MQ-AS)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg/day for three days)
Study: 7786658
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 infusion
Study: 21699364
Drug: Vaseline® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaseline® cream (placebo)
Study: 15005829
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (caffeine 104 mg/d, catechins 573 mg/d, 323 mg epigallocatechin gallate)
Study: 8216453
Drug: Gel formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel formulation (Iprogel)
Study: 8216453
Drug: Hydrophilic ointment
Normalized name: HYDROPHILIC OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic ointment
Study: 8216453
Drug: Emulsion cream
Normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion cream (reference product)
Study: 29940521
Drug: Psychoeducational Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational Cognitive Behavioural Group Therapy (PCBT-G)
Study: 29940521
Drug: PCBT-G plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCBT-G plus 16 outpatient individual treatment sessions (PCBT-G+I)
Study: 29940521
Drug: PCBT-G and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCBT-G and PCBT-G+I
Study: 29940521
Drug: PCBT-G+I
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCBT-G+I
Study: 29940521
Drug: PCBT-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCBT-G
Study: 27136509
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water immersion (8.9±0.6°C; 9 min with 1 min out of water, repeated twice)
Study: 15752125
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol (0.005%) applied twice daily
Study: 1514500
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched to nifedipine doses)